Based on this background, this study hypothesizes that polymorphisms in OPRM1 and OPRD1 influence the response to opioids, thereby conditioning their therapeutic effectiveness and toxicity in patients with advanced-stage colorectal cancer. Here, OPRM1 is linked to colorectal cancer.